Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Change in Acquisitions & Divestments: 2019-2025

Historic Change in Acquisitions & Divestments for Intellia Therapeutics (NTLA) over the last 7 years, with Sep 2025 value amounting to $115.9 million.

  • Intellia Therapeutics' Change in Acquisitions & Divestments fell 41.94% to $115.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $778.6 million, marking a year-over-year decrease of 17.39%. This contributed to the annual value of $1.1 billion for FY2024, which is 20.27% up from last year.
  • Per Intellia Therapeutics' latest filing, its Change in Acquisitions & Divestments stood at $115.9 million for Q3 2025, which was down 28.76% from $162.7 million recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' Change in Acquisitions & Divestments peaked at $321.6 million during Q4 2024, and registered a low of $73.3 million during Q2 2021.
  • In the last 3 years, Intellia Therapeutics' Change in Acquisitions & Divestments had a median value of $213.0 million in 2023 and averaged $219.2 million.
  • As far as peak fluctuations go, Intellia Therapeutics' Change in Acquisitions & Divestments spiked by 397.97% in 2021, and later plummeted by 41.94% in 2025.
  • Over the past 5 years, Intellia Therapeutics' Change in Acquisitions & Divestments (Quarterly) stood at $94.6 million in 2021, then surged by 122.16% to $210.2 million in 2022, then decreased by 6.17% to $197.2 million in 2023, then soared by 63.08% to $321.6 million in 2024, then slumped by 41.94% to $115.9 million in 2025.
  • Its last three reported values are $115.9 million in Q3 2025, $162.7 million for Q2 2025, and $178.3 million during Q1 2025.